d-Cycloserine-Augmented Behavior Therapy for Body Dysmorphic Disorder: A Preliminary Efficacy Trial
Cognitive behavioral therapy (CBT) is the leading psychotherapeutic treatment for body dysmorphic disorder (BDD), yet not all patients improve. To address the treatment response gap, CBT may be augmented with cognitive enhancers such as d-cycloserine (DCS). DCS-augmented behavior therapy has been tested with mixed results in related disorders. To initially test whether DCS may augment CBT for BDD, we conducted the first preliminary efficacy trial of DCS versus placebo-augmented CBT for BDD, via a randomized, double-blind study. We analyzed data using mixed-effects models in a modified intent-to-treat sample (N = 26). Over 10 weeks of treatment, primary (BDD severity) and secondary (insight, depression) outcomes improved significantly across both conditions, but there were no significant group differences in response. Exploratory analysis revealed that BDD-related distress, specifically, reduced significantly more in the DCS condition compared to placebo. This is the first study testing DCS-augmented CBT for BDD. Implications, limitations, and future directions are discussed.
Trial registry: ClinicalTrials.gov Identifier NCT00842309
KeywordsBody dysmorphic disorder Behavior therapy d-Cycloserine Cognitive enhancers
We would like to thank the reviewers, whose comments on an earlier version of this manuscript contributed to substantial improvements in the paper.
This work was supported by the Neil and Anna Rasmussen Foundation and the David Judah Fund. The funding sources played no role in design of this study; the collection, analysis, and interpretation of data; the writing of this report; or the decision to submit this article for publication.
Compliance with Ethical Standards
Conflict of interest
Drs. Weingarden and Wilhelm and Ms. Ladis have received salary support from Telefonica Alpha, Inc. Dr. Wilhelm has received research support in the form of free medication and matching placebo from Forest Laboratories for clinical trials funded by the NIH. Dr. Wilhelm is a presenter for the Massachusetts General Hospital Psychiatry Academy in educational programs supported through independent medical education grants from pharmaceutical companies; she has received royalties from Elsevier Publications, Guilford Publications, New Harbinger Publications, and Oxford University Press. Dr. Wilhelm has also received speaking honorarium from various academic institutions and foundations, including the International Obsessive Compulsive Disorder Foundation and the Tourette Association of America. In addition, she received payment from the Association for Behavioral and Cognitive Therapies for her role as Associate Editor for the Behavior Therapy journal, as well as from John Wiley & Sons, Inc. for her role as Associate Editor on the journal Depression & Anxiety. Dr. Wilhelm has also received salary support from Novartis. Dr. Dougherty has received research support from Medtronic and LivaNova. Suraj S. Mothi, Susanne Hoeppner, Hannah E. Reese, Kiara Timpano, Jedidiah Siev, Jessica Rasmussen and Jennifer Ragan declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
No animal studies were carried out by the authors for this article.
- Andersson, E., Hedman, E., Enander, J., Djurfeldt, D. R., Ljótsson, B., Cervenka, S., Isung, J., Svanborg, C., Mataix-Cols, D., Kaldo, V., Andersson, G., Lindefors, N., & Rück, C. (2015). d-Cycloserine vs placebo as adjunct to cognitive behavioral therapy for obsessive-compulsive disorder and interaction with antidepressants: A randomized clinical trial. JAMA Psychiatry, 72, 659–667. https://doi.org/10.1001/jamapsychiatry.2015.0546.CrossRefPubMedGoogle Scholar
- Beck, A. T., Steer, R. A., & Brown, G. K. (1996). Beck depression inventory-second edition: manual. San Antonio, TX: Psychological Corporation.Google Scholar
- Chasson, G. S., Buhlmann, U., Tolin, D. F., Rao, S. R., Reese, H. E., Rowley, T., Welsh, K., & Wilhelm, S. (2010). Need for speed: Evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine. Behaviour Research and Therapy, 48, 675–679. https://doi.org/10.1016/j.brat.2010.03.007.CrossRefPubMedGoogle Scholar
- Farrell, L. J., Waters, A. M., Boschen, M. J., Hattingh, L., McConnell, H., Milliner, E. L., Collings, N., Zimmer-Gembeck, M., Shelton, D., Ollendick, T. H., Testa, C., & Storch, E. A. (2013). Difficult-to-treat pediatric obsessive-compulsive disorder: Feasibility and preliminary results of a randomized pilot trial of d-cycloserine-augmented behavior therapy. Depression and Anxiety, 30, 723–731. https://doi.org/10.1002/da.22132.CrossRefPubMedGoogle Scholar
- First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. (2002). The structured clinical interview for the DSM-IV-TR Axis I disorders (SCID-I/P). (Research version, patient ed.). New York: Biometrics Research.Google Scholar
- Guastella, A. J., Richardson, R., Lovibond, P. F., Rapee, R. M., Gaston, J. E., Mitchell, P., & Dadds, M. R. (2008). A randomized controlled trial of d-cycloserine enhancement of exposure therapy for social anxiety disorder. Biological Psychiatry, 63, 544–549. https://doi.org/10.1016/j.biopsych.2007.11.011.CrossRefPubMedGoogle Scholar
- Hedges, L., & Olkin, I. (1985). Statistical methods for meta-analysis. New York: Academic Press.Google Scholar
- Hofmann, S. G., Carpenter, J. K., Otto, M. W., Rosenfield, D., Smits, J. A. J., & Pollack, M. H. (2015). Dose timing of d-cycloserine to augment cognitive behavioral therapy for social anxiety: Study design and rationale. Contemporary Clinical Trials, 43, 223–230. https://doi.org/10.1016/j.cct.2015.06.015.CrossRefPubMedGoogle Scholar
- Hofmann, S. G., Meuret, A. E., Smits, J. A., Simon, N. M., Pollack, M. H., Eisenmenger, K., Shiekh, M., & Otto, M. W. (2006). Augmentation of exposure therapy with d-cycloserine for social anxiety disorder. Archives of General Psychiatry, 63, 298. https://doi.org/10.1001/archpsyc.63.3.298.CrossRefPubMedGoogle Scholar
- Hofmann, S. G., Smits, J. A., Rosenfield, D., Simon, N. M., Otto, M. W., Meuret, A. E., Fang, A., Tart, C., & Pollack, M. H. (2013). d-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. America Journal of Psychiatry, 170, 751–758. https://doi.org/10.1176/appi.ajp.2013.12070974.CrossRefGoogle Scholar
- Kushner, M. G., Kim, S. W., Donahue, C., Thuras, P., Adson, D., Kotlyar, M., McCabe, J., Peterson, J., & Foa, E. B. (2007). D-Cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biological Psychiatry, 62, 835–838. https://doi.org/10.1016/j.biopsych.2006.12.020.CrossRefPubMedGoogle Scholar
- Mataix-Cols, D., Fernández de la Cruz, L., Monzani, B., Rosenfield, D., Andersson, E., Pérez-Vigil, A., & Rück, C. (2017). D-Cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: A systematic review and meta-analysis of individual participant data. JAMA Psychiatry, 74, 501–510. https://doi.org/10.1001/jamapsychiatry.2016.3955.CrossRefPubMedGoogle Scholar
- Mataix-Cols, D., Turner, C., Monzani, B., Isomura, K., Murphy, C., Krebs, G., & Heyman, I. (2014). Cognitive-behavioural therapy with post-session D-cycloserine augmentation for paediatric obsessive-compulsive disorder: Pilot randomised controlled trial. British Journal of Psychiatry, 204, 77–78. https://doi.org/10.1192/bjp.bp.113.126284.CrossRefPubMedGoogle Scholar
- Otto, M. W., Kredlow, M. A., Smits, J. A. J., Hofmann, S. G., Tolin, D. F., de Kleine, R. A., van Minnen, A., Evins, A. E., & Pollack, M. H. (2016). Enhancement of psychosocial treatment with d-cycloserine: Models, moderators, and future directions. Biological Psychiatry, 80, 274–283. https://doi.org/10.1016/j.biopsych.2015.09.007.CrossRefPubMedGoogle Scholar
- SAS Institute, Inc. (2016). The SAS system for Windows, version 9.4. Cary, NC: SAS Institute, Inc.Google Scholar
- Smits, J. A. J., Rosenfield, D., Otto, M. W., Marques, L., Davis, M. L., Meuret, A. E., Simon, N. M., Pollack, M. H., & Hofmann, S. G. (2013). d-Cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. Journal of Psychiatric Research, 47, 1455–1461. https://doi.org/10.1016/j.jpsychires.2013.06.020.CrossRefPubMedGoogle Scholar
- Storch, E. A., Merlo, L. J., Bengtson, M., Murphy, T. K., Lewis, M. H., Yang, M. C., Jacob, M. L., Larson, M., Hirch, A., Fernandez, M., Geffken, G. R., & Goodman, W. K. (2007). D-Cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. International Clinical Psychopharmacology, 22, 230–237. https://doi.org/10.1097/YIC.0b013e32819f8480.CrossRefPubMedGoogle Scholar
- Storch, E. A., Murphy, T. K., Goodman, W. K., Geffken, G. R., Lewin, A. B., Henin, A., Micco, J. A., Sprich, S., Wilhelm, S., Bengston, M., & Geller, D. A. (2010). A preliminary study of D-cycloserine augmentation of cognitive-nehavioral therapy in pediatric obsessive-compulsive disorder. Biological Psychiatry, 68, 1073–1076. https://doi.org/10.1016/j.biopsych.2010.07.015.CrossRefPubMedGoogle Scholar
- Storch, E. A., Wilhelm, S., Sprich, S., Henin, A., Micco, J., Small, B. J., McGuire, J., Mutch, P. J., Lewin, A. B., Murphy, T. K., & Geller, D. A. (2016). Efficacy of augmentation of cognitive behavior therapy with weight-adjusted d-cycloserine vs placebo in pediatric obsessive-compulsive disorder: A randomized clinical trial. JAMA Psychiatry, 73, 779–788. https://doi.org/10.1001/jamapsychiatry.2016.1128.CrossRefPubMedGoogle Scholar
- Veale, D., Anson, M., Miles, S., Pieta, M., Costa, A., & Ellison, N. (2014). Efficacy of cognitive behaviour therapy versus anxiety management for body dysmorphic disorder: A randomised controlled trial. Psychotherapy and Psychosomatics, 83, 341–353. https://doi.org/10.1159/000360740.CrossRefPubMedGoogle Scholar
- Walker, D. L., Ressler, K. J., Lu, K. T., & Davis, M. (2002). Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. The Journal of Neuroscience, 22, 2343–2351.CrossRefPubMedGoogle Scholar
- Wilhelm, S., Buhlmann, U., Tolin, D. F., Meunier, S. A., Pearlson, G. D., Reese, H. E., Cannistraro, P., Jenike, M. A., & Rauch, S. L. (2008). Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. American Journal of Psychiatry, 165, 335–341. https://doi.org/10.1176/appi.ajp.2007.07050776. (quiz 409).CrossRefPubMedGoogle Scholar
- Wilhelm, S., Phillips, K. A., Didie, E., Buhlmann, U., Greenberg, J. L., Fama, J. M., Keshaviah, A., & Steketee, G. (2014). Modular cognitive-behavioral therapy for body dysmorphic disorder: A randomized controlled trial. Behavior Therapy, 45, 314–327. https://doi.org/10.1016/j.beth.2013.12.007.CrossRefPubMedGoogle Scholar
- Wilhelm, S., Phillips, K. A., & Steketee, G. (2013). Cognitive-behavioral therapy for body dysmorphic disorder: A treatment manual. New York: Guilford Press.Google Scholar